Company profile
Ticker
MBX
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
New PennyMac Financial Services, Inc.
SEC CIK
Corporate docs
MBX stock data
Latest filings (excl ownership)
8-K
Amendments to Articles of Incorporation or Bylaws
16 Sep 24
S-8
Registration of securities for employees
13 Sep 24
424B5
Prospectus supplement for primary offering
13 Sep 24
EFFECT
Notice of effectiveness
13 Sep 24
S-1MEF
Registration of additional securities for an S-1
12 Sep 24
CERT
Certification of approval for exchange listing
12 Sep 24
8-A12B
Registration of securities on exchange
10 Sep 24
S-1/A
IPO registration (amended)
9 Sep 24
S-1/A
IPO registration (amended)
30 Aug 24
S-1
IPO registration
23 Aug 24
Latest ownership filings
SC 13D
Norwest Venture Partners XVI, LP
23 Sep 24
SC 13D
New Enterprise Associates 17, L.P.
23 Sep 24
SC 13D
ORBIMED ADVISORS LLC
23 Sep 24
SC 13G
Deep Track Capital, LP
23 Sep 24
SC 13D
Frazier Life Sciences Public Fund, L.P.
23 Sep 24
SC 13G
Wellington Biomedical Innovation Master Investors (Cayman) II L.P.
20 Sep 24
4
Edward T Mathers
17 Sep 24
4
FOREST BASKETT
17 Sep 24
4
Ali Behbahani
17 Sep 24
4
Carmen Chang
17 Sep 24
Institutional ownership, Q2 2024
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Sep 24 | Wellington Biomedical Innovation Master Investors | Common Stock | Conversion | Acquire C | No | No | 0 | 403,787 | 0.00 | 1,790,122 |
16 Sep 24 | Wellington Biomedical Innovation Master Investors | Common Stock | Conversion | Acquire C | No | No | 0 | 1,386,335 | 0.00 | 1,386,335 |
16 Sep 24 | Wellington Biomedical Innovation Master Investors | Series C Preferred Stock Common Stock | Conversion | Dispose C | No | No | 0 | 4,854,368 | 0.00 | 0 |
16 Sep 24 | Wellington Biomedical Innovation Master Investors | Series B Preferred Stock Common Stock | Conversion | Dispose C | No | No | 0 | 16,666,666 | 0.00 | 0 |
16 Sep 24 | Gordon Carl L | Common Stock | Buy | Acquire P | Yes | No | 16 | 250,000 | 4.00 mm | 653,787 |
16 Sep 24 | Gordon Carl L | Common Stock | Buy | Acquire P | Yes | No | 16 | 500,000 | 8.00 mm | 3,158,428 |
16 Sep 24 | Gordon Carl L | Common Stock | Conversion | Acquire C | Yes | No | 0 | 403,787 | 0.00 | 403,787 |
16 Sep 24 | Gordon Carl L | Common Stock | Conversion | Acquire C | Yes | No | 0 | 2,658,428 | 0.00 | 2,658,428 |
16 Sep 24 | Gordon Carl L | Series C Convertible Preferred Stock Common Stock | Conversion | Dispose C | Yes | No | 0 | 4,854,368 | 0.00 | 0 |
16 Sep 24 | Gordon Carl L | Series B Convertible Preferred Stock Common Stock | Conversion | Dispose C | Yes | No | 0 | 19,587,284 | 0.00 | 0 |
News
Reported Earlier, MBX Biosciences Prices Initial Public Offering Of 10.20M Common Shares At $16/Share
13 Sep 24
Mbx Biosciences, Inc To Start Trading Tomorrow
12 Sep 24
Clinical-Stage Biopharmaceutical Company MBX Biosciences Plans Launch Of Its IPO Of 8.50M Shares Of Its Common Stock At Estimated Price Of $14 - $16 Per Share
9 Sep 24